Join Growin Stock Community!

益得6461.TW Overview

TW StockBiotech. & Medical
(No presentation for 6461)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

益得（6461）Overall Performance

益得（6461）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

益得（6461） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

益得（6461）Key Information

益得（6461）Profile

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

益得（6461）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-90.97%
Net Margin
-325.29%
Revenue Growth (YoY)
218.68%
Profit Growth (YoY)
36.33%
3-Year Revenue Growth
8.59%
3-Year Profit Growth
-10.65%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-90.97%
Net Margin
-325.29%
Revenue Growth (YoY)
218.68%
Profit Growth (YoY)
36.33%
3-Year Revenue Growth
8.59%
3-Year Profit Growth
-10.65%
default symbol

6461

益得

23.90D

-4.81%

(-0.05)

  • When is 6461's latest earnings report released?

    The most recent financial report for 益得 (6461) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6461's short-term business performance and financial health. For the latest updates on 6461's earnings releases, visit this page regularly.

  • What is the operating profit of 6461?

    According to the latest financial report, 益得 (6461) reported an Operating Profit of -140M with an Operating Margin of -1,923.1% this period, representing a decline of 52.68% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6461's revenue growth?

    In the latest financial report, 益得 (6461) announced revenue of 7.28M, with a Year-Over-Year growth rate of -15.89%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6461 have?

    At the end of the period, 益得 (6461) held Total Cash and Cash Equivalents of 72.34M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6461 go with three margins increasing?

    In the latest report, 益得 (6461) did not achieve the “three margins increasing” benchmark, with a gross margin of -662.66%%, operating margin of -1,923.1%%, and net margin of -1,979.15%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6461's profit trajectory and future growth potential.

  • Is 6461's EPS continuing to grow?

    According to the past four quarterly reports, 益得 (6461)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.88. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6461?

    益得 (6461)'s Free Cash Flow (FCF) for the period is 66.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 727.81% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.